Eleonora FranzÃ¨

List of Publications by Year
in descending order

44 papers	1,434 citations	331670 21 h-index	345221 36 g-index
44 all docs	44 docs citations	44 times ranked	2289 citing authors

#	Article	IF	Citations
1	The Deubiquitinating Enzyme OTUD5 Sustains Inflammatory Cytokine Response in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 122-132.	1.3	12
2	GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation. Journal of Crohn's and Colitis, 2022, 16, 301-311.	1.3	15
3	Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Frontiers in Immunology, 2022, 13, 873332.	4.8	4
4	The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 639-658.	4.5	21
5	Interleukin-34 promotes tumorigenic signals for colon cancer cells. Cell Death Discovery, 2021, 7, 245.	4.7	7
6	Cadherin-11 Is a Regulator of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2020, 14, 406-417.	1.3	24
7	Interleukin-34 Enhances the Tumor Promoting Function of Colorectal Cancer-Associated Fibroblasts. Cancers, 2020, 12, 3537.	3.7	18
8	Macrophages produce and functionally respond to interleukin-34 in colon cancer. Cell Death Discovery, 2020, 6, 117.	4.7	13
9	Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. Cancers, 2020, 12, 1314.	3.7	13
10	Role of Interleukin-34 in Cancer. Cancers, 2020, 12, 252.	3.7	29
11	Interleukin-34 Stimulates Gut Fibroblasts to Produce Collagen Synthesis. Journal of Crohn's and Colitis, 2020, 14, 1436-1445.	1.3	30
12	Expression of Receptors for SARS-CoV-2 in the Gut of Patients with Inflammatory Bowel Disease. Gut and Liver, 2020, 14, 530-531.	2.9	7
13	Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. Cancer Letters, 2019, 462, 1-11.	7.2	13
14	Progranulin sustains <scp>STAT</scp>3 hyperâ€activation and oncogenic function in colorectal cancer cells. Molecular Oncology, 2019, 13, 2142-2159.	4.6	17
15	Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis. Frontiers in Immunology, 2019, 10, 2158.	4.8	42
16	Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 772-784.	1.3	150
17	NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals. Frontiers in Pharmacology, 2019, 10, 380.	3.5	19
18	Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice. Inflammatory Bowel Diseases, 2018, 24, 1213-1224.	1.9	22

#	Article	IF	Citations
19	Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clinical Science, 2018, 132, 1155-1168.	4.3	53
20	Reciprocal Regulation Between Smad7 and Sirt1 in the Gut. Frontiers in Immunology, 2018, 9, 1854.	4.8	13
21	RORÎ³t-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Cancer Immunology Research, 2018, 6, 1082-1092.	3.4	35
22	Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget, 2018, 9, 3432-3445.	1.8	57
23	Follistatin-like protein 1 sustains colon cancer cell growth and survival. Oncotarget, 2018, 9, 31278-31290.	1.8	8
24	Smad7 knockdown activates protein kinase RNA-associated eIF2Î± pathway leading to colon cancer cell death. Cell Death and Disease, 2017, 8, e2681-e2681.	6.3	20
25	Aryl hydrocarbon receptorâ€driven signals inhibit collagen synthesis in the gut. European Journal of Immunology, 2016, 46, 1047-1057.	2.9	38
26	Interleukin-34 Induces Cc-chemokine Ligand 20 in Gut Epithelial Cells. Journal of Crohn's and Colitis, 2016, 10, 87-94.	1.3	46
27	Interleukin-34 sustains inflammatory pathways in the gut. Clinical Science, 2015, 129, 271-280.	4.3	57
28	Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. Oncotarget, 2015, 6, 9908-9923.	1.8	47
29	Defective Expression of Scavenger Receptors in Celiac Disease Mucosa. PLoS ONE, 2014, 9, e100980.	2.5	8
30	Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. Journal of Immunology, 2014, 192, 6083-6091.	0.8	67
31	IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology, 2013, 58, 1436-1450.	7.3	45
32	High Expression of the â€œA Disintegrin And Metalloproteaseâ€•19 (ADAM19), a Sheddase for TNF-Î± in the Mucosa of Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2013, 19, 501-511.	1.9	19
33	Lesional Accumulation of CD163-Expressing Cells in the Gut of Patients with Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e69839.	2.5	30
34	2-Methoxy-5-amino-<i>N</i>-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms. Clinical Science, 2012, 123, 295-306.	4.3	1
35	Tissue Inhibitor of Metalloproteinase-3 Regulates Inflammation in Human and Mouse Intestine. Gastroenterology, 2012, 143, 1277-1287.e4.	1.3	36
36	Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflammatory Bowel Diseases, 2012, 18, 449-459.	1.9	42

#	Article	IF	Citations
37	Interleukin-25 fails to activate STAT6 and induce alternatively activated macrophages. Immunology, 2011, 132, 66-77.	4.4	11
38	Targeting interleukin-21 in inflammatory diseases. Expert Opinion on Therapeutic Targets, 2011, 15, 695-702.	3.4	31
39	2-Methoxy-5-Amino-<i>N</i>-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression. Molecular Cancer Therapeutics, 2011, 10, 1969-1981.	4.1	17
40	Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. Journal of Experimental Medicine, 2011, 208, 2279-2290.	8.5	126
41	Interleukin-25 Negatively Controls Pathogenic Responses in the Gut. Inflammation and Allergy: Drug Targets, 2011, 10, 187-191.	1.8	7
42	Characterization of IL-17Aâ€“Producing Cells in Celiac Disease Mucosa. Journal of Immunology, 2010, 184, 2211-2218.	0.8	106
43	Involvement of interleukin-15 and interleukin-21, two Î³-chain-related cytokines, in celiac disease. World Journal of Gastroenterology, 2009, 15, 4609.	3.3	27
44	Molecular basis of the potential of mesalazine to prevent colorectal cancer. World Journal of Gastroenterology, 2008, 14, 4434.	3.3	31